Friday, September 08, 2006

Introgen Cancer Drug Shows Promise

Biopharmaceutical company Introgen Therapeutics Inc. said Wednesday data from a mid-stage study of its breast cancer treatment were published in the latest issue of Cancer, the journal of the American Cancer Society. The Phase II clinical trial, involving 12 patients, combined Advexin and chemotherapy to shrink tumors before surgical removal. The study showed a more than 50 percent reduction in tumor size and a 100 percent success rate in complete removal of the tumors during surgery. After 37 months, the survival rate for patients was 84 percent. The study was conducted at the University of Texas M.D. Anderson Cancer Center. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */